CA2132208A1 - Method of Eliminating Inhibitory/Instability Regions of mRNA - Google Patents

Method of Eliminating Inhibitory/Instability Regions of mRNA

Info

Publication number
CA2132208A1
CA2132208A1 CA 2132208 CA2132208A CA2132208A1 CA 2132208 A1 CA2132208 A1 CA 2132208A1 CA 2132208 CA2132208 CA 2132208 CA 2132208 A CA2132208 A CA 2132208A CA 2132208 A1 CA2132208 A1 CA 2132208A1
Authority
CA
Canada
Prior art keywords
mrna
constructs
inhibitory
instability
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2132208
Other languages
French (fr)
Other versions
CA2132208C (en
Inventor
George N. Pavlakis
Barbara K. Felber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Government
Original Assignee
George N. Pavlakis
Barbara K. Felber
The Government Of The United States Of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by George N. Pavlakis, Barbara K. Felber, The Government Of The United States Of America filed Critical George N. Pavlakis
Publication of CA2132208A1 publication Critical patent/CA2132208A1/en
Application granted granted Critical
Publication of CA2132208C publication Critical patent/CA2132208C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

A method of locating an inhibitory/instability sequence or sequences within the coding region of an mRNA and modifying the gene encoding that mRNA to remove these inhibitory/instability sequences by making clustered nucleotide substitutions without altering the coding capacity of the gene is disclosed. Constructs containing these mutated genes and host cells containing these constructs are also disclosed. The method and constructs are exemplified by the mutation of a Human Immunodeficiency Virus-1 Rev-dependent gag gene to a Rev-independent gag gene. Constructs useful in locating inhibitory/instability sequences within either the coding region or the 3' untranslated region of an mRNA are also disclosed. The exemplified constructs of the invention may also be useful in HIV-1 immunotherapy and immunoprophylaxis.
CA002132208A 1992-03-27 1993-03-29 Method of eliminating inhibitory/instability regions of mrna Expired - Lifetime CA2132208C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/858,747 US6174666B1 (en) 1992-03-27 1992-03-27 Method of eliminating inhibitory/instability regions from mRNA
US07/858,747 1992-03-27
PCT/US1993/002908 WO1993020212A1 (en) 1992-03-27 1993-03-29 METHOD OF ELIMINATING INHIBITORY/INSTABILITY REGIONS OF mRNA

Publications (2)

Publication Number Publication Date
CA2132208A1 true CA2132208A1 (en) 1993-10-14
CA2132208C CA2132208C (en) 1999-09-14

Family

ID=25329086

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002132208A Expired - Lifetime CA2132208C (en) 1992-03-27 1993-03-29 Method of eliminating inhibitory/instability regions of mrna

Country Status (7)

Country Link
US (6) US6174666B1 (en)
EP (1) EP0635062B1 (en)
JP (4) JP4180650B2 (en)
AU (1) AU678157B2 (en)
CA (1) CA2132208C (en)
DE (1) DE69327456T2 (en)
WO (1) WO1993020212A1 (en)

Families Citing this family (190)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3765103B2 (en) * 1992-02-28 2006-04-12 シンジェニックス・リミテッド Defective packaging non-oncovirus vector based on MPMV and HIV
US6174666B1 (en) * 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US6995008B1 (en) 1994-03-07 2006-02-07 Merck & Co., Inc. Coordinate in vivo gene expression
AUPM772494A0 (en) * 1994-08-30 1994-09-22 Austin Research Institute, The Improvements in production of proteins in host cells
AU709401B2 (en) * 1994-08-30 1999-08-26 Austin Research Institute, The Improvements in production of proteins in host cells
WO1998003669A2 (en) * 1996-07-22 1998-01-29 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vectors for inhibiting hiv and tumor growth
DE69739351D1 (en) * 1996-12-16 2009-05-20 Eisai R&D Man Co Ltd DNA construct comprising a drug resistance gene and a foreign gene
AU1087299A (en) * 1997-10-14 1999-05-03 Avant Immunotherapeutics, Inc. Non-integrating dna vector of retroviral origin having high-protein expres sion, and secreted immunogenic antigens
US7598079B2 (en) * 1998-12-24 2009-10-06 Novation Pharmaceuticals, Inc. Assay for identifying compounds which affect stability of mRNA
GB9828709D0 (en) * 1998-12-24 1999-02-17 Novartis Ag Assay
CA2360347C (en) 1998-12-31 2013-05-07 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
CA2358915C (en) 1998-12-31 2010-06-01 Chiron Corporation Modified hiv env polypeptides
CA2358385C (en) 1998-12-31 2013-08-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
US6656706B2 (en) * 1999-12-23 2003-12-02 The United States Of America As Represented By The Department Of Health And Human Services Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
EP1246913B1 (en) * 1999-12-23 2009-08-05 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Molecular clones with mutated hiv gag/pol, siv gag and siv env genes
US6582920B2 (en) * 2000-09-01 2003-06-24 Gen-Probe Incorporated Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations
ATE414794T1 (en) * 2000-09-01 2008-12-15 Gen Probe Inc AMPLIFICATION OF HIV-1 SEQUENCES FOR DETECTION OF SEQUENCES ASSOCIATED WITH DRUG RESISTANCE MUTATIONS
WO2002029088A2 (en) 2000-10-04 2002-04-11 The Trustees Of The University Of Pennsylvania Highly expressible genes
JP2002125687A (en) * 2000-10-30 2002-05-08 Tosoh Corp Oligonucleotide for detecting hiv-1 and method for detecting the same
CA2427257C (en) * 2000-11-01 2014-01-21 The Government Of The United States Of America Expression vectors able to elicit improved immune response and methods of using same
JP4701532B2 (en) * 2001-04-26 2011-06-15 東ソー株式会社 Amplification and detection of HIV-1 RNA
ES2340532T3 (en) 2001-06-05 2010-06-04 Curevac Gmbh MRNA WITH AN INCREASED G / C CONTENT THAT CODIFIES FOR A BACTERIAL ANTIGEN AND USING THE SAME.
US7205278B2 (en) 2001-06-14 2007-04-17 The Scripps Research Institute Stabilized proteins with engineered disulfide bonds
US20040136963A1 (en) * 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
EP1409012B1 (en) * 2001-06-22 2009-02-11 The Wistar Institute Of Anatomy And Biology Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein
JP5033303B2 (en) * 2001-07-05 2012-09-26 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Polynucleotides encoding polypeptides with antigenic type C HIV, polypeptides and uses thereof
US20030198621A1 (en) * 2001-07-05 2003-10-23 Megede Jan Zur Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
CA2458995C (en) * 2001-08-31 2013-04-30 Chiron Corporation Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
US6835568B2 (en) * 2001-10-30 2004-12-28 Virxsys Corporation Regulated nucleic acid expression system
ES2258601T3 (en) 2001-11-13 2006-09-01 The Trustees Of The University Of Pennsylvania A METHOD FOR THE IDENTIFICATION OF THE UNKNOWN SEQUENCES OF ADENO-ASSOCIATED VIRUSES (VAA) AND A KIT FOR THE METHOD.
EP1944043A1 (en) 2001-11-21 2008-07-16 The Trustees of the University of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
CA2466431C (en) 2001-11-21 2014-08-05 The Trustees Of The University Of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
DE10162480A1 (en) 2001-12-19 2003-08-07 Ingmar Hoerr The application of mRNA for use as a therapeutic agent against tumor diseases
US7943146B2 (en) * 2001-12-21 2011-05-17 Myrexis, Inc. Immunizing compositions comprising HIV-1 proviral constructs with an inactive p6 gag TSG101 UEV binding domain capable of producing budding-defective viral particles that remain tethered to the cell surface
US20050075298A1 (en) * 2002-01-31 2005-04-07 Wei Chen Methods and composition for delivering nucleic acids and/or proteins to the intestinal mucosa
US20040043003A1 (en) * 2002-01-31 2004-03-04 Wei Chen Clinical grade vectors based on natural microflora for use in delivering therapeutic compositions
US20040009937A1 (en) * 2002-01-31 2004-01-15 Wei Chen Methods and composition for delivering nucleic acids and/or proteins to the respiratory system
US6974762B2 (en) * 2002-08-01 2005-12-13 Intel Corporation Adhesion of carbon doped oxides by silanization
AU2002953015A0 (en) * 2002-12-02 2002-12-12 Women's And Children's Hospital Modified lacz gene
CN1301263C (en) * 2002-12-18 2007-02-21 北京昭衍新药研究中心 Nucleotide sequence for anti HIV infection and preventing AIDS and use thereof
AU2003301148A1 (en) * 2002-12-23 2004-07-22 Vical Incorporated Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
US8426194B2 (en) 2003-01-21 2013-04-23 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating VEGF expression
EP1604011A4 (en) 2003-01-21 2009-12-09 Ptc Therapeutics Inc Methods for identifying compounds that modulate untranslated region-dependent gene expression and methods of using same
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
CA2567116A1 (en) * 2004-06-04 2005-12-15 Wyeth Enhancing protein expression
EP1763590A2 (en) 2004-06-07 2007-03-21 The Government of the United States of America, as represented by the Secretary, Department of Health & Human Services Real-time pcr point mutation assays for detecting hiv-1 resistance to antiviral drugs
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
EP2359865B1 (en) 2005-04-07 2013-10-02 The Trustees of The University of Pennsylvania Method of increasing the function of an AAV vector
PL1899364T3 (en) 2005-05-17 2020-08-24 University Of Connecticut Compositions and methods for immunomodulation in an organism
CN102796743B (en) 2006-01-13 2015-11-18 美国政府健康及人类服务部国立卫生研究院 For codon optimized IL-15 and the IL-15R α gene of expressing in mammalian cell
EP2468298B1 (en) 2006-07-13 2015-09-02 Institute For Advanced Study Methods of optimizing vaccine production
US8283115B1 (en) 2007-06-20 2012-10-09 Ptc Therapeutics, Inc. Methods of screening for compounds for treating muscular dystrophy using UTRN mRNA translation regulation
US8283116B1 (en) 2007-06-22 2012-10-09 Ptc Therapeutics, Inc. Methods of screening for compounds for treating spinal muscular atrophy using SMN mRNA translation regulation
ES2466916T3 (en) 2007-06-27 2014-06-11 Admune Therapeutics Llc IL-15 and IL-15R alpha complexes and uses thereof
PL2220241T3 (en) 2007-11-28 2017-06-30 The Trustees Of The University Of Pennsylvania Adenovirus comprising a Simian E Adenovirus SAdV-39 capsid hexon protein and uses thereof
EP2463362B1 (en) 2007-11-28 2017-11-08 The Trustees Of The University Of Pennsylvania Simian subfamily c adenovirus SAdv-31 and uses thereof
EP2250255A2 (en) 2008-03-04 2010-11-17 The Trustees of the University of Pennsylvania Simian adenoviruses sadv-36,-42.1, -42.2, and -44 and uses thereof
WO2009140206A1 (en) 2008-05-11 2009-11-19 The Gov. Of The U. S. A., As Represented By The Secretary Of The Dept. Of Health And Human Services Improved expression of il-12 family heterodimers
US7561972B1 (en) 2008-06-06 2009-07-14 Dna Twopointo, Inc. Synthetic nucleic acids for expression of encoded proteins
US8126653B2 (en) * 2008-07-31 2012-02-28 Dna Twopointo, Inc. Synthetic nucleic acids for expression of encoded proteins
US7561973B1 (en) 2008-07-31 2009-07-14 Dna Twopointo, Inc. Methods for determining properties that affect an expression property value of polynucleotides in an expression system
US8401798B2 (en) * 2008-06-06 2013-03-19 Dna Twopointo, Inc. Systems and methods for constructing frequency lookup tables for expression systems
JP5809978B2 (en) 2008-10-31 2015-11-11 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Simian adenovirus SAdV-43, -45, -46, -47, -48, -49 and -50 and their uses
CA2762203A1 (en) 2009-05-29 2010-12-02 Soumitra Roy Simian adenovirus 41 and uses thereof
WO2011106705A2 (en) 2010-02-26 2011-09-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Dna-protein vaccination protocols
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
US20120237975A1 (en) 2010-10-01 2012-09-20 Jason Schrum Engineered nucleic acids and methods of use thereof
US9725689B2 (en) 2010-10-08 2017-08-08 Terumo Bct, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
WO2012071318A2 (en) 2010-11-23 2012-05-31 The Trustees Of The University Of Pennsylvania Subfamily e simian adenoviruses a1321, a1325, a1295, a1309, a1316 and a1322 and uses thereof
EP2668210B1 (en) 2011-01-26 2020-06-17 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
SI2691530T1 (en) 2011-06-10 2018-08-31 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
WO2012174001A1 (en) 2011-06-13 2012-12-20 Abgenomics Cooperatief U.A. Anti-psgl-1 antibodies and uses thereof
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2850624A1 (en) 2011-10-03 2013-04-11 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
KR20140102759A (en) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 Modified nucleoside, nucleotide, and nucleic acid compositions
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
CA2868398A1 (en) 2012-04-02 2013-10-10 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
MX358019B (en) 2012-05-18 2018-08-02 Univ Pennsylvania Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof.
ES2631608T3 (en) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Env-glycoprotein variant of HIV-1
US9334332B2 (en) 2012-07-25 2016-05-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
JP6359019B2 (en) 2012-10-24 2018-07-18 ノバルティス アーゲー IL-15Rα type, cells expressing IL-15Rα type, and therapeutic use of IL-15Rα and IL-15 / IL-15Rα complex
JP6144355B2 (en) 2012-11-26 2017-06-07 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． Chemically modified mRNA
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (en) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Polynucleotide encoding low density lipoprotein receptor
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
ES2806575T3 (en) 2013-11-01 2021-02-18 Curevac Ag Modified RNA with decreased immunostimulatory properties
CN105992816B (en) 2013-11-16 2018-04-17 泰尔茂比司特公司 Cell amplification in bioreactor
JP6783143B2 (en) 2014-03-25 2020-11-11 テルモ ビーシーティー、インコーポレーテッド Passive replenishment of medium
MA44179B1 (en) 2014-05-13 2020-10-28 Univ Pennsylvania Compositions comprising an adeno-associated virus expressing double antibody constructs and their uses
MA47849A (en) 2014-05-28 2020-01-29 Agenus Inc ANTI-GITR ANTIBODIES AND THEIR METHODS OF USE
US10335460B2 (en) 2014-07-29 2019-07-02 Novartis Ag IL-15 and IL-15Rα heterodimer dose escalation regimens for treating conditions
CN106715676A (en) 2014-09-26 2017-05-24 泰尔茂比司特公司 Scheduled feed
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
SG11201708804WA (en) 2015-05-07 2017-11-29 Agenus Inc Anti-ox40 antibodies and methods of use thereof
ES2959642T3 (en) 2015-05-13 2024-02-27 The Us Secretary Of The Department Of Health And Human Services METHODS AND COMPOSITIONS TO INDUCE AN IMMUNE RESPONSE THROUGH CONSTRUCTIONS WITH CONSERVED ELEMENTS
SG10201913500TA (en) 2015-05-29 2020-03-30 Agenus Inc Anti-ctla-4 antibodies and methods of use thereof
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
EA201890630A1 (en) 2015-09-01 2018-10-31 Эйдженус Инк. ANTIBODIES AGAINST PD-1 AND METHODS OF THEIR APPLICATION
JP7118887B2 (en) 2015-11-23 2022-08-16 ノバルティス アーゲー Optimized lentiviral transfer vectors and their uses
US10472422B2 (en) 2016-01-08 2019-11-12 Abgenomics International Inc. Tetravalent anti-PSGL-1 antibodies and uses thereof
EP3443108A4 (en) 2016-04-15 2019-11-20 The Trustees of The University of Pennsylvania Novel aav8 mutant capsids and compositions containing same
EP3464565A4 (en) 2016-05-25 2020-01-01 Terumo BCT, Inc. Cell expansion
MX2018014387A (en) 2016-05-27 2019-03-14 Agenus Inc Anti-tim-3 antibodies and methods of use thereof.
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
KR20190039937A (en) 2016-07-08 2019-04-16 스태튼 바이오테크놀로지 비.브이. Anti-ApoC3 antibodies and methods of use thereof
WO2018013855A2 (en) 2016-07-14 2018-01-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Il-15/il-15 receptor alpha treatment regimens and use with therapeutic vaccines
TW202246349A (en) 2016-10-11 2022-12-01 美商艾吉納斯公司 Anti-lag-3 antibodies and methods of use thereof
MX2019006340A (en) 2016-12-07 2019-11-07 Agenus Inc Anti-ctla-4 antibodies and methods of use thereof.
EA201991204A1 (en) 2016-12-22 2019-12-30 Университа Дельи Студи Манья Греча Катандзаро MONOCLONAL ANTIBODY AGAINST UNIQUE Sialoglycosylated Tumor-Associated Epitope CD43
KR20190103226A (en) 2017-01-13 2019-09-04 아게누스 인코포레이티드 T cell receptor that binds to NY-ESO-1 and methods of use thereof
CA3046120A1 (en) 2017-01-20 2018-07-26 Novartis Ag Combination therapy for the treatment of cancer
EP3570870A1 (en) 2017-01-20 2019-11-27 Novartis AG Combination therapy for the treatment of cancer
BR112019017260A2 (en) 2017-02-17 2020-04-14 Camris Int Inc universal antivenom
JP7393945B2 (en) 2017-03-31 2023-12-07 テルモ ビーシーティー、インコーポレーテッド cell proliferation
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
BR112019017241A2 (en) 2017-04-13 2020-04-14 Agenus Inc anti-cd137 antibodies and methods of using them
CN110506056A (en) 2017-04-21 2019-11-26 斯塔滕生物技术有限公司 Anti- APOC3 antibody and its application method
EP3618863B1 (en) 2017-05-01 2023-07-26 Agenus Inc. Anti-tigit antibodies and methods of use thereof
WO2018229706A1 (en) 2017-06-16 2018-12-20 Novartis Ag Combination therapy for the treatment of cancer
CN110831965B (en) 2017-06-21 2023-03-07 吉利德科学公司 Multispecific antibodies targeting HIV GP120 and CD3
WO2019040780A1 (en) 2017-08-25 2019-02-28 Five Prime Therapeutics Inc. B7-h4 antibodies and methods of use thereof
JP7387585B2 (en) 2017-09-04 2023-11-28 アジェナス インコーポレイテッド T-cell receptor that binds mixed lineage leukemia (MLL)-specific phosphopeptide and methods of use thereof
CA3080103A1 (en) 2017-10-31 2019-05-09 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
SG11202007240QA (en) 2018-02-02 2020-08-28 Novartis Ag Combination of sting agonist and il-15/il15-ra for the treatment of cancer
WO2019165075A1 (en) 2018-02-21 2019-08-29 Five Prime Therapeutics, Inc. B7-h4 antibody dosing regimens
CA3091174A1 (en) 2018-02-21 2019-08-29 Five Prime Therapeutics, Inc. B7-h4 antibody formulations
BR112020017925A2 (en) 2018-03-02 2020-12-22 Five Prime Therapeutics, Inc. ANTIBODIES AGAINST B7-H4 AND METHODS OF USE OF THE SAME
US10870691B2 (en) 2018-04-05 2020-12-22 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis B virus protein X
SG11202012043RA (en) 2018-07-03 2021-01-28 Gilead Sciences Inc Antibodies that target hiv gp120 and methods of use
CN112969503A (en) 2018-10-03 2021-06-15 斯塔滕生物技术有限公司 Antibodies specific for human and cynomolgus macaques APOC3 and methods of use thereof
AU2019361923A1 (en) 2018-10-15 2021-06-03 Five Prime Therapeutics, Inc. Combination therapy for cancer
EP3990476A1 (en) 2019-06-25 2022-05-04 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
US11795210B2 (en) 2019-07-16 2023-10-24 Gilead Sciences, Inc. HIV vaccines and methods of making and using
US11680098B2 (en) 2019-08-30 2023-06-20 Agenus Inc. Antibodies that specifically bind human CD96
CN114555799A (en) 2019-09-30 2022-05-27 吉利德科学公司 HBV vaccines and methods for treating HBV
WO2021094984A1 (en) 2019-11-14 2021-05-20 Aelix Therapeutics, S.L. Dosage regimens for vaccines
EP4100425A1 (en) 2020-02-05 2022-12-14 Novartis AG Cho cell expressing il-15 heterodimers
WO2021167964A1 (en) 2020-02-18 2021-08-26 Alector Llc Pilra antibodies and methods of use thereof
IL295979A (en) 2020-03-06 2022-10-01 Ona Therapeutics S L Anti-cd36 antibodies and their use to treat cancer
WO2021214658A1 (en) 2020-04-22 2021-10-28 Novartis Ag Pharmaceutical compositions and pharmaceutical products of heterodimeric human interleukin-15 (hetil-15)
JP2023528235A (en) 2020-05-17 2023-07-04 アストラゼネカ・ユーケイ・リミテッド SARS-CoV-2 Antibodies and Methods of Selecting and Using The Same
CN116507636A (en) 2020-07-20 2023-07-28 阿斯利康(英国)有限公司 SARS-CoV-2 proteins, anti-SARS-CoV-2 antibodies and methods of use thereof
KR20230051208A (en) 2020-08-14 2023-04-17 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Novel AAV capsids and compositions containing them
CN116761821A (en) 2020-08-18 2023-09-15 赛福伦有限责任公司 anti-PAR-2 antibodies and methods of use thereof
KR20230054456A (en) 2020-08-25 2023-04-24 길리애드 사이언시즈, 인코포레이티드 Multispecific Antigen Binding Molecules Targeting HIV and Methods of Using The Same
EP4228610A1 (en) 2020-10-13 2023-08-23 Kriya Therapeutics, Inc. Viral vector constructs for delivery of nucleic acids encoding cytokines and uses thereof for treating cancer
TWI815194B (en) 2020-10-22 2023-09-11 美商基利科學股份有限公司 INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE
CA3196499A1 (en) 2020-10-29 2022-05-05 James M. Wilson Aav capsids and compositions containing same
CN116744970A (en) 2020-12-11 2023-09-12 北卡罗来纳大学教堂山分校 Compositions and methods comprising SFRP2 antagonists
CA3202466A1 (en) 2021-01-14 2022-07-21 Jiani LI Hiv vaccines and methods of using
US20240092885A1 (en) 2021-01-26 2024-03-21 Kriya Therapeutics, Inc. Vector constructs for delivery of nucleic acids encoding therapeutic anti-tnf antibodies and methods of using the same
KR20230158476A (en) 2021-02-19 2023-11-20 빔 테라퓨틱스, 인크. Recombinant rabies virus for gene therapy
IL308404A (en) 2021-04-27 2024-01-01 Generation Bio Co Non-viral dna vectors expressing therapeutic antibodies and uses thereof
TW202309066A (en) 2021-04-27 2023-03-01 賓州大學委員會 Porcine-derived adeno-associated virus capsids and uses thereof
TW202313094A (en) 2021-05-18 2023-04-01 美商基利科學股份有限公司 Methods of using flt3l-fc fusion proteins
IL309349A (en) 2021-06-14 2024-02-01 argenx BV Anti-il-9 antibodies and methods of use thereof
CA3223292A1 (en) 2021-06-25 2022-12-29 Laura Van Lieshout Adeno-associated virus packaging systems
WO2023007472A1 (en) 2021-07-30 2023-02-02 ONA Therapeutics S.L. Anti-cd36 antibodies and their use to treat cancer
CA3230629A1 (en) 2021-09-08 2023-03-16 Beam Therapeutics Inc. Viral guide rna delivery
CA3235018A1 (en) 2021-10-15 2023-04-20 Leila M. BOUSTANY Activatable polypeptide complex
WO2023064955A1 (en) 2021-10-15 2023-04-20 Cytomx Therapeutics, Inc. Activatable anti-cd3, anti-egfr, heteromultimeric bispecific polypeptide complex
WO2023064927A1 (en) 2021-10-15 2023-04-20 Cytomx Therapeutics, Inc. Activatable polypeptide complex
CA3234162A1 (en) 2021-10-15 2023-04-20 Michele Fiscella Antibodies and methods of using thereof
WO2023114901A2 (en) 2021-12-15 2023-06-22 Oxford Biomedica Solutions Llc Methods and compositions for the production of adeno-associated virus
WO2023133561A1 (en) 2022-01-09 2023-07-13 Kriya Therapeutics, Inc. Vector constructs for delivery of nucleic acids encoding therapeutic anti-igf-1r antibodies and methods of using the same
WO2023154678A1 (en) 2022-02-08 2023-08-17 Amgen Inc. Codon-optimized nucleic acids encoding ocrelizumab
WO2023177655A1 (en) 2022-03-14 2023-09-21 Generation Bio Co. Heterologous prime boost vaccine compositions and methods of use
WO2023194796A2 (en) 2022-04-04 2023-10-12 Vectory B.V. Recombinant aav capsid proteins
WO2023209177A1 (en) 2022-04-29 2023-11-02 Astrazeneca Uk Limited Sars-cov-2 antibodies and methods of using the same
WO2023242633A2 (en) 2022-06-14 2023-12-21 Vectory B.V. Recombinant aav capsid proteins
WO2023242372A1 (en) 2022-06-15 2023-12-21 argenx BV Fcrn/hsa binding molecules and methods of use
WO2023248008A2 (en) 2022-06-20 2023-12-28 Vectory B.V. Degron fusion constructs
WO2024015741A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof
WO2024015966A2 (en) 2022-07-15 2024-01-18 The Trustees Of The University Of Pennsylvania Recombinant aav having aav clade d and clade e capsids and compositions containing same
WO2024026471A1 (en) 2022-07-29 2024-02-01 Alector Llc Cd98hc antigen-binding domains and uses therefor
WO2024026472A2 (en) 2022-07-29 2024-02-01 Alector Llc Transferrin receptor antigen-binding domains and uses therefor
WO2024040132A2 (en) 2022-08-16 2024-02-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Synergistic interactions for improved cancer treatment
WO2024054993A1 (en) 2022-09-09 2024-03-14 Kriya Therapeutics, Inc. Vector constructs for delivery of nucleic acids encoding therapeutic anti-ctla4 antibodies and methods of using the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US33653A (en) * 1861-11-05 Improvement in swivel hooks and rings
US4652639A (en) 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4959455A (en) * 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
IL89567A0 (en) 1988-03-28 1989-09-10 Univ Leland Stanford Junior Mutated hiv envelope protein
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US5082767A (en) * 1989-02-27 1992-01-21 Hatfield G Wesley Codon pair utilization
ES2200016T3 (en) * 1989-03-21 2004-03-01 Vical Incorporated EXPRESSION OF EXECUTIVE POLINUCLEOTIDIC SEQUENCES IN A VERTEBRATE.
US4970491A (en) 1989-04-03 1990-11-13 Trams Enterprises, Inc. Air pressure alert system
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
US6174666B1 (en) * 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA

Also Published As

Publication number Publication date
US5965726A (en) 1999-10-12
US6291664B1 (en) 2001-09-18
US5972596A (en) 1999-10-26
US6794498B2 (en) 2004-09-21
JP2007209345A (en) 2007-08-23
CA2132208C (en) 1999-09-14
JP2009165497A (en) 2009-07-30
AU3969493A (en) 1993-11-08
EP0635062A1 (en) 1995-01-25
US6174666B1 (en) 2001-01-16
US6414132B1 (en) 2002-07-02
DE69327456T2 (en) 2000-08-10
AU678157B2 (en) 1997-05-22
JP4336371B2 (en) 2009-09-30
JP4180650B2 (en) 2008-11-12
EP0635062B1 (en) 1999-12-29
DE69327456D1 (en) 2000-02-03
US20020192660A1 (en) 2002-12-19
JP2010252809A (en) 2010-11-11
WO1993020212A1 (en) 1993-10-14
JPH07509121A (en) 1995-10-12

Similar Documents

Publication Publication Date Title
CA2132208A1 (en) Method of Eliminating Inhibitory/Instability Regions of mRNA
Erickson et al. Lack of the D2 protein in a Chlamydomonas reinhardtii psb D mutant affects photosystem II stability and D1 expression
EP0320500A3 (en) Non-oncogenic ti plasmid vector system and recombinant dna molecules for the introduction of expressible genes into plant cell genomes
ES2009238A6 (en) Mycobacterial recombinants and peptides
GB9902660D0 (en) Plant gene
SE8603145L (en) PROCEDURE FOR THE PREPARATION OF INTERFERON-BETA
GB8601597D0 (en) Nucleotide sequences
CA2015077A1 (en) A yeast cell of the genus schwanniomyces
EP0305488A4 (en) Mycobacterial recombinants and peptides
ES8607397A1 (en) Human factor VIII, Compositions containing it, methods and materials for use in it production.
DE3586189T2 (en) QUANTITY AND METHOD FOR PRODUCING RECOMBINED PRODUCTS IN LARGE YIELD.
NO950534L (en) Modified fungal cells and methods for producing recombinant products
BG103334A (en) Antiviral vectors
EP0370458A3 (en) Synthetic DNA derived recombinant HIV-1 antigens
AU6823296A (en) Viral material and nucleotide fragments associated with multiple sclerosis, for diagnostic, prophylactic and therapeutic purposes
MY105816A (en) Thermally stable cytosine deaminase.
AU649640B2 (en) A method of preparing a plasmid, the plasmid and expression products thereof
Williams et al. The nucleotide sequence of the major β-globin mRNA from Xenopus laevis
EP1262554A3 (en) Defective packaging non-oncoviral vectors based on mpmv and hiv
ATE152769T1 (en) RIBOFLAVIN SYNTHESIS IN YEAST
IL94482A (en) Transdominant repressor mutant of retroviral protein, dna encoding the protein and process for their preparation and use thereof
AU4569293A (en) Anti-feline immunodeficiency virus (fiv) vaccines
Lohia et al. Heterogeneity of Entamoeba histolytica rac genes encoding p21rac homologues
FI80905C (en) DNA and the extensive vector
EP0169505A2 (en) Process for preparing oligopeptide

Legal Events

Date Code Title Description
EEER Examination request